Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a
Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a human monoclonal antibody for the diagnosis and staging of colorectal cancer that PerImmune is developing. Syncor also announced that it has completed its acquisition of the iodine-123 business of Golden Pharmaceuticals of Golden, CO (SCAN 2/19/97).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.